Celularity’s mission is to harness the power
of the living cell to augment biology,
immunity and longevity.
Celularity is a biotechnology company that productizes allogeneic cells and tissues derived from the postpartum placenta. These materials have the ability to augment our immunity and longevity by amplifying the body’s ability to fight disease, heal, and regenerate itself.
why the placenta?
Celularity is the only company to use an allogenic placental platform. Because stem cells derived from the placenta are intrinsically safe, they can be taken from any placenta and injected into any human without the risk of rejection. These cells are also incredibly abundant, making treatments more affordable and immediate.
BIRTHS PER YEAR
Celularity, through its strategic partner Sorrento Therapeutics, has acquired a powerful toolset to engineer cells for broad immunotherapeutic applications.
These include proprietary antibody and Chimeric Antigen Receptor (CAR) constructs that will allow Celularity to offer the world’s first immunotherapeutic suite of products against novel targets for cancer and immune disease. In addition, Celularity discovered a Natural Killer cell from the placenta and is actively developing therapeutic uses.
Celularity is developing the world’s first allogeneic off-the-shelf CAR-T cell receptor and CAR-NK products against a number of validated targets for immuno-oncology.
Studies have shown as we age the population of stem cells resident in our organs and tissues declines exponentially, diminishing our body’s ability to heal and repair itself. Moreover, during our lifetime, our stem cells are damaged by environmental exposures rendering them less effective and adaptable.
By replenishing our reservoir of stem cells –– nature’s repair kit –– on an ongoing basis, we can augment our longevity.
Celularity seeks to make 100 years old the new 60, and to provide people with maximal aesthetics, mobility, and cognition as they age. We believe the 20 years of science, research, and intellectual property Celularity is built on is the cornerstone for the coming longevity revolution.
Celularity’s placental technology platform uses stem cells derived from the placenta to create therapeutic options for complex medical conditions ranging from cancer to Crohn’s disease. Celularity is the leader in cellular medicine with the deepest and broadest intellectual property portfolio of more than 800 issued patents.
Read the latest publications relating to Celularity’s science.
BOB HARIRI, MD, PhD
FOUNDER, CHAIRMAN & CEO
Dr. Robert (Bob) Hariri is the Founder, Chairman and CEO of Celularity.
He has worked for the past 20 years to transform the field of biomedicine where his discoveries and contributions to the study of stem cells and tissue engineering have sparked the development of nearly all existing stem cell therapies. In addition to Celularity, he is the Founder, and former Chairman and CEO of Celgene Cellular Therapeutics, a division of Celgene Corporation. He is also the Co-Founder and Vice Chairman of Human Longevity Inc.
CHIEF OPERATING OFFICER
JOHN R. HAINES
EVP, CHIEF ADMINISTRATIVE OFFICER
XIAOKUI ZHANG, PHD
EVP, CHIEF SCIENTIFIC OFFICER
Celgene, Rockefeller University
EVP, CHIEF INNOVATION OFFICER
TIMOTHY L. SMITH, JD PHD
EVP, GENERAL COUNSEL
Human Longevity, Novartis
SVP, CHIEF COMMERCIAL OFFICER
Celgene, Pfizer, Pharmacia
SVP, INVESTOR & PUBLIC RELATIONS
JP Morgan, American Express
SVP, FINANCE & CONTROLLER
SVP, HUMAN RESOURCES
Celgene, Nabisco, Kraft Foods
BOARD OF DIRECTORS
PETER DIAMANDIS, MD
CO-FOUNDER & VICE CHAIRMAN
Dr. Peter Diamandis is the Founder & Executive Chairman of the XPRIZE and Executive Founder of Singularity University. He has Co-Founded 20 companies including Human Longevity Inc. Diamandis is the NY Times Bestselling author of Abundance & BOLD. He earned degrees in Molecular Genetics and Aerospace Engineering at MIT, and an M.D. from Harvard Medical School. Fortune Magazine recently named Diamandis as on of the World’s 50 Greatest Leaders.
John Sculley is an American businessman and formerly Chief Executive Officer of Apple Inc and President of Pepsi-Cola. The companies John has advised cover many industries: health-tech (RxAdvance, Rally Health, MDLIVE, FLEXPharma, SleepMed); fin-tech (Lantern Credit); mobile-tech (MetroPCS); and marketing-tech (Zeta Interactive). Sculley received a bachelor’s degree in Architectural Design from Brown University and an MBA from the Wharton School of the University of Pennsylvania.
Founder, Section 32
ANDREW C. VON ESCHENBACH, MD
Former Commissioner, United States FDA
HENRI JI, PhD
Co-Founder & CEO, Sorrento Therapeutics
Chief Executive Officer, Senmur Pharmaceuticals
ANDREW PECORA, MD, FACP, CPE
Chief Innovation Officer, John Thereur Cancer Center
Former Head, JPM Healthcare Investment Banking Group